Stock SRTOY SARTORIUS STEDIM BIOTECH S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sartorius Stedim Biotech S.A. OTC Markets

Equities

SRTOY

US80386Y1010

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets
Other stock markets
 02:19:41 2024-07-12 pm EDT 		5-day change 1st Jan Change
18.61 USD +3.10% Intraday chart for Sartorius Stedim Biotech S.A. +8.20% -32.15%
Jul. 10 Markets Powered by Alternating Current Our Logo
Jul. 09 Mixed feelings Our Logo

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,615 26,843 44,467 27,883 22,073 16,377 - -
Enterprise Value (EV) 1 13,723 27,370 44,869 28,912 25,638 18,641 18,535 18,203
P/E ratio 58.1 x 75.1 x 107 x 31.8 x 71.3 x 49.4 x 35.5 x 27.7 x
Yield 0.46% 0.23% 0.26% 0.48% - 0.44% 0.55% 0.68%
Capitalization / Revenue 9.45 x 14.1 x 15.4 x 7.98 x 7.95 x 5.62 x 5.01 x 4.46 x
EV / Revenue 9.53 x 14.3 x 15.5 x 8.28 x 9.24 x 6.39 x 5.67 x 4.96 x
EV / EBITDA 32.6 x 45.3 x 43.4 x 23.7 x 32.6 x 21.1 x 17.8 x 14.9 x
EV / FCF 78.8 x 106 x 121 x 159 x - 47.6 x 54.6 x 40.2 x
FCF Yield 1.27% 0.94% 0.83% 0.63% - 2.1% 1.83% 2.49%
Price to Book 11.7 x 18.4 x 26.9 x 11.4 x - 3.98 x 3.64 x 3.27 x
Nbr of stocks (in thousands) 92,180 92,180 92,179 92,177 92,163 97,311 - -
Reference price 2 147.7 291.2 482.4 302.5 239.5 168.3 168.3 168.3
Announcement Date 1/28/20 2/18/21 1/27/22 1/26/23 1/26/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,441 1,910 2,887 3,493 2,776 2,916 3,270 3,670
EBITDA 1 421.5 604.7 1,033 1,221 785.4 882.1 1,042 1,222
EBIT 1 332 471.8 865.4 1,040 - 634.2 771.1 935.4
Operating Margin 23.05% 24.7% 29.98% 29.77% - 21.75% 23.58% 25.49%
Earnings before Tax (EBT) 1 317.6 482.6 646.7 1,130 - 471.1 667.3 849.2
Net income 1 234.6 357.8 414.4 876.1 309.7 315.3 428.6 544.3
Net margin 16.28% 18.73% 14.35% 25.08% 11.16% 10.81% 13.11% 14.83%
EPS 2 2.540 3.880 4.500 9.510 3.360 3.405 4.744 6.067
Free Cash Flow 1 174.2 257.7 372 181.7 - 391.3 339.5 453.3
FCF margin 12.09% 13.49% 12.88% 5.2% - 13.42% 10.38% 12.35%
FCF Conversion (EBITDA) 41.32% 42.62% 36% 14.88% - 44.36% 32.6% 37.1%
FCF Conversion (Net income) 74.24% 72.03% 89.76% 20.74% - 124.12% 79.22% 83.29%
Dividend per Share 2 0.6800 0.6800 1.260 1.440 - 0.7342 0.9182 1.149
Announcement Date 1/28/20 2/18/21 1/27/22 1/26/23 1/26/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - 1,352 757 779 - 862.5 861.8 878.4 890 726.1 675.7 666.9 706.8 666.9 699.2 725.7 775.5 -
EBITDA 1 - - 487.4 278.1 267.9 - 303.7 303.3 304.9 309.5 220.1 195.6 178.3 191.4 191 196.4 220.7 237.7 -
EBIT 1 164.8 265.3 - 238.7 221.4 451.3 263 260.6 262.7 253.4 171.5 145.2 76.9 - 120.6 161.9 179.9 196.7 -
Operating Margin - - - 31.53% 28.42% - 30.49% 30.24% 29.91% 28.47% 23.62% 21.49% 11.53% - 18.08% 23.16% 24.79% 25.37% -
Earnings before Tax (EBT) 1 - - - 209.5 63.82 - 337.8 283.2 273.5 235.9 148.6 158.9 35.5 - 77 134.9 152.9 171.2 -
Net income 1 - - - 147.7 8.213 - 270.1 214.8 204.5 186.7 111.1 133.1 25.7 39.8 56.1 74.55 87.83 107.5 -
Net margin - - - 19.51% 1.05% - 31.32% 24.92% 23.28% 20.98% 15.3% 19.7% 3.85% 5.63% 8.41% 10.66% 12.1% 13.86% -
EPS 2 - - - 1.600 0.0900 - 2.930 2.330 2.220 2.030 1.210 1.440 0.2800 0.4300 0.5800 0.7660 0.9024 1.104 -
Dividend per Share 2 - - - - 1.260 - - - - 1.440 - - - - 0.2393 0.2184 0.2184 0.2184 0.2613
Announcement Date 1/28/20 2/18/21 7/21/21 10/20/21 1/27/22 1/27/22 4/21/22 7/21/22 10/19/22 1/26/23 4/20/23 7/21/23 10/19/23 1/26/24 4/18/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 108 527 402 1,029 3,565 2,264 2,158 1,826
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.2555 x 0.8715 x 0.3889 x 0.8421 x 4.539 x 2.567 x 2.072 x 1.494 x
Free Cash Flow 1 174 258 372 182 - 391 340 453
ROE (net income / shareholders' equity) 21.4% 27.3% 26.8% 42.7% - 12.5% 13.2% 14.7%
ROA (Net income/ Total Assets) 13.8% 15.6% 12.2% 19.4% - 5.29% 6.2% 7.34%
Assets 1 1,696 2,291 3,404 4,509 - 5,964 6,917 7,419
Book Value Per Share 2 12.60 15.80 18.00 26.60 - 42.30 46.20 51.40
Cash Flow per Share 2 3.360 4.520 7.550 6.640 - 5.540 6.310 7.850
Capex 1 136 159 324 431 474 374 342 365
Capex / Sales 9.44% 8.33% 11.22% 12.33% 17.06% 12.81% 10.48% 9.94%
Announcement Date 1/28/20 2/18/21 1/27/22 1/26/23 1/26/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sartorius Stedim Biotech S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
168.3 EUR
Average target price
240.6 EUR
Spread / Average Target
+42.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.31% 181B
MEDTRONIC PLC Stock Medtronic plc
-5.38% 100B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-6.04% 65.01B
HOYA CORPORATION Stock Hoya Corporation
+16.45% 45.75B
DEXCOM, INC. Stock DexCom, Inc.
-8.08% 44.8B
CENCORA, INC. Stock Cencora, Inc.
+8.38% 43.72B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+12.06% 29.01B
TERUMO CORPORATION Stock Terumo Corporation
+17.98% 26.03B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.28% 24.28B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. DIM Stock
  4. SRTOY Stock
  5. Financials Sartorius Stedim Biotech S.A.